Pronota – MyCartis

Pronota N.V. devel­ops diag­nos­tics using a tech­nol­o­gy plat­form that unique­ly mines for nov­el low-abun­dance pro­tein bio­mark­ers in blood.

The lead pro­gram of Pronota is in pre-eclamp­sia, a con­di­tion of late preg­nan­cy that can severe­ly impact the health of moth­er and child.

Portfolio: MedSciences Capital II B.V.

Current prod­uct devel­op­ment stage: clin­i­cal val­i­da­tion.
Merged into MyCartis N.V.